Randomized Phase III Trial of 131iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)
Year: 2011
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: University of Nebraska Medical Center, Emmes (United States), University of Minnesota Medical Center, Moffitt Cancer Center, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, Abramson Cancer Center, University of Pennsylvania, University of Michigan, Johns Hopkins University, Medical College of Wisconsin
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2574905185